News and Trends 5 Jun 2020
Upsized Nasdaq IPO Yields Calliditas €80M to Commercialize Kidney Drug
Swedish company Calliditas Therapeutics has raised an €80M IPO on the Nasdaq Global Select Market — 20% above its initial target — to fund an ongoing phase III trial of its lead candidate treatment for an inflammatory kidney condition. Calliditas plans to use the net proceeds together with its existing cash resources to fund an […]